New England Journal of Medicine publishes long-term results of Gleevec ®

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news